Bionano Genomics (BNGO)
(Delayed Data from NSDQ)
$0.41 USD
-0.01 (-3.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $0.41 0.00 (1.11%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum D VGM
Price, Consensus and EPS Surprise
BNGO 0.41 -0.01(-3.45%)
Will BNGO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BNGO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BNGO
Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now
Bionano Genomics (BNGO) Upgraded to Buy: Here's Why
BNGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
Other News for BNGO
BTIG downgrades Bionano to Neutral after fourth workforce reduction
BTIG gets more bearish on Bionano Genomics, downgrades shares
Bionano lowered 2024 revenue outlook to $32M-$36M from $36M-$40M
Bionano Genomics announces departure of CFO Gulsen Kama
Bionano Genomics lays off 45% of staff, or 84 employees